StockNews.AISignal intelligence
Liquidia Corporation · NASDAQ · Healthcare
Browse public LQDA signals with their source context and measured market impact. Open any signal for its permanent analysis page.
A federal judge ruled Liquidia's lung drug infringes United Therapeutics' patent, triggering a roughly 50% stock drop. The decision jeopardizes near-term commercialization and could erase expected revenue, prompting potential appeals or licensing negotiations that may alter the company’s development timeline.
View signal analysisLiquidia Corp reported impressive Q1 results, exceeding both earnings and sales estimates, leading to a 3.1% share price increase. Analysts from Wells Fargo and HC Wainwright upgraded their price targets, reflecting renewed confidence in LQDA's growth potential. This momentum suggests a robust outlook for LQDA's stock performance in the near term.
View signal analysisLiquidia Corporation reported $148.3 million in sales for YUTREPIA in 2025, along with strong prescription growth. The company achieved profitability for two consecutive quarters and ended the year with a robust cash position, enhancing prospects for continued expansion and clinical advancement of products like L606.
View signal analysisLQDA reported a second-quarter loss of 49 cents per share. Sales reached $8.84 million, surpassing expectations significantly. FDA approved YUTREPIA with strong initial market demand of over 900 prescriptions. Analysts have raised price targets, indicating bullish sentiment. Shares gained 2.6%, trading at $24.72 after the announcement.
View signal analysisLQDA reported a Q2 loss of 49 cents, missing expectations. Sales reached $8.84 million, beating the consensus of $3.86 million. FDA approved Yutrepia, now shipping to U.S. customers. Interim data from clinical trials shows promising findings for Yutrepia. LQDA stock gained 14.13%, trading at $24.20.
View signal analysisFDA approved Liquidia's Yutrepia for PAH and PH-ILD treatment. Liquidia shares fell 5.2% to $14.80 despite FDA approval. Wells Fargo raised the price target from $20 to $23. HC Wainwright maintained Buy and raised target from $29 to $35. Needham reiterated Buy with a $25 price target.
View signal analysis